We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
1.25 | 1.28% | 98.98 | 99.075 | 98.54 | 98.60 | 789,293 | 19:36:59 |
By Olivia Bugault
Novartis AG said Tuesday that its Zolgensma gene therapy for patients with spinal muscular atrophy has been conditionally approved in Europe.
The European Commission granted the approval for the treatment to Novartis's subsidiary AveXis, while also specifying the conditions under which it can be used in the E.U.
Zolgensma has been approved for use in patients with certain types of spinal muscular atrophy, the pharmaceutical giant said. "The approval covers babies and young children with SMA up to 21kg according to the approved dosing guidance," it added.
Following the approval, AveXis is now in talks with E.U. member states and reimbursements agencies to agree on final pricing terms that are decided at local level and enable a quick access to the gene therapy.
AveXis has launched a program called "Day One" that proposes different options of access and reimbursement to ministries of health and reimbursement bodies, it said.
Spinal muscular atrophy is a genetic neuromuscular disease that results in the irreversible loss of motor neurons.
Write to Olivia Bugault at olivia.bugault@wsj.com
(END) Dow Jones Newswires
May 19, 2020 02:04 ET (06:04 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions